Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 1 (January 1), 2007: pp. 70-76
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.07.4393

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chew, H. K.
Right arrow Articles by White, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chew, H. K.
Right arrow Articles by White, R. H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients

Helen K. Chew, Theodore Wun, Danielle J. Harvey, Hong Zhou, Richard H. White

From the Divisions of Hematology/Oncology and General Medicine, Department of Internal Medicine; the Department of Public Health Sciences, University of California Davis; and the Section of Hematology and Oncology, VA Northern California Health Care System, Sacramento, CA

Address reprint requests to Helen K. Chew, MD, Division of Hematology/Oncology, 4501 X St, Suite 3016, Sacramento, CA 95817; e-mail: helen.chew{at}ucdmc.ucdavis.edu

Purpose The incidence of venous thromboembolism (VTE) and the risk factors associated with development of VTE have not been reported in a large population-based study of breast cancer patients.

Patients and Methods The California Cancer Registry was merged with the Patient Discharge Data Set, and the number of VTE events determined among patients diagnosed between 1993 and 1999.

Results Among 108,255 patients with breast cancer, the 2-year cumulative VTE incidence was 1.2%, with a rate of 1.2 and 0.6 events/100 patient-years during the first and second half-year, respectively. The 1-year incidence of VTE was significantly increased compared with the general population (standardized incidence ratio of VTE, 4.2; 95% CI, 3.9 to 4.4). In a multivariate model, significant predictors of developing VTE within 2 years were: age (hazard ratio [HR], 2.0 if > 75 years v < 45; 95% CI, 1.6 to 2.6), the number of chronic medical comorbidities (HR, 2.9 if 3 v 0; 95% CI, 2.4 to 3.5), and advancing cancer stage (HR, 6.3; 95% CI, 5.3 to 7.5 for metastatic v local disease). In multivariate models, VTE was a significant predictor of decreased 2-year survival (HR, 2.3; 95% CI, 2.1 to 2.6) and when stratified by initial cancer stage, the effect was highest in patients with localized (HR, 5.1; 95% CI, 3.6 to 7.1) or regional stage (HR, 3.5; 95% CI, 2.5 to 4.8) cancer compared with patients with metastatic disease (HR, 1.9; 95% CI, 1.5 to 2.4).

Conclusion Approximately 1% of breast cancer patients developed VTE within 2 years, with the highest incidence in the first 6 months after diagnosis. Metastatic disease and comorbidities were the strongest predictors. The diagnosis of VTE was associated with a higher risk of death within 2 years.

Supported in part by National Institutes of Health Grant No. 1-RO3- CA99527-01 (H.K.C.).

Presented in part at the 28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
A. A. Khorana and G. C. Connolly
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
J. Clin. Oncol., October 10, 2009; 27(29): 4839 - 4847.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. M. Kuderer, T. L. Ortel, and C. W. Francis
Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival
J. Clin. Oncol., October 10, 2009; 27(29): 4902 - 4911.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. H. Lyman and A. A. Khorana
Cancer, Clots and Consensus: New Understanding of an Old Problem
J. Clin. Oncol., October 10, 2009; 27(29): 4821 - 4826.
[Full Text] [PDF]


Home page
JCOHome page
C. Ay, R. Vormittag, D. Dunkler, R. Simanek, A.-L. Chiriac, J. Drach, P. Quehenberger, O. Wagner, C. Zielinski, and I. Pabinger
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
J. Clin. Oncol., September 1, 2009; 27(25): 4124 - 4129.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, and A. R. Norman
Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
J. Clin. Oncol., August 10, 2009; 27(23): 3786 - 3793.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. H. Ku, R. H. White, H. K. Chew, D. J. Harvey, H. Zhou, and T. Wun
Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival
Blood, April 23, 2009; 113(17): 3911 - 3917.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. Vescia, A. K. Baumgartner, V. R. Jacobs, M. Kiechle-Bahat, A. Rody, S. Loibl, and N. Harbeck
Management of venous port systems in oncology: a review of current evidence
Ann. Onc., January 1, 2008; 19(1): 9 - 15.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman
The Risk of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Mandala, M. Reni, S. Cascinu, S. Barni, I. Floriani, S. Cereda, R. Berardi, S. Mosconi, V. Torri, and R. Labianca
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients
Ann. Onc., October 1, 2007; 18(10): 1660 - 1665.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online